Loading
Varex Imaging Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 14 Aug 2024.
Varex Imaging Corp: what insiders have been doing
Varex Imaging Corp is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). Between 18 October 2025 and 18 October 2026, 13 insiders published 18 filings.
Only sales appear on the open market, 2 sales in all totalling €2.1M, filed by 2 insiders. At €2.1M, the sale published on 15 September 2026 by Maheshwari Shubham is the largest of the period (0.30% of market cap).
For context, the typical company on the same exchange (median of 5,812 companies) published 19 filings over the same period, against 18 filings here. The full history, which starts in 2021, counts 2 purchases against 16 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 3 October 2025), the company reported revenue of 844.6 m USD and net income of -70.3 m USD.
The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Cytosorbents Corp. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
94
Thresholds
n/a
Buy Volume
€189,537
2 ops. · all time
Sell Volume
€3M
16 ops. · all time
Who traded when
BuySaleKunkel Jay K.4 sales
Karen L. Aranki1 sale
Kimberley E. Honeysett1 sale
Shubham Maheshwari1 sale
Sunny Sanyal1 sale
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 17,928 of 24,148 companies
35.2
score / 100
Value35
Quality36
FCF yld2.4%
Earn yld-9.0%
EV/EBITDA·
ROE4.6%
Gross mgn34%
Net mgn-8.3%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended September 2025 · cache
US$18.39
Analyst consensus
2 analysts3.00/5
US$18.90Target US$18.90(+3%)US$18.90
Income statement
RevenueUS$844.6M
Gross profitUS$290.5M34% margin
EBITDAUS$700k0% margin
Net income-US$70.3M2.6% margin
Valuation
PER (trailing)34.7x
PER (forward)17.2x
P/Book1.6x
Beta0.97
Balance sheet & cash
Market capUS$780.9M
Total debtUS$395.9M
Free Cash FlowUS$18.8M
Debt / Equity74%
Profitability & ownership
ROE4.6%
ROA4.2%
% insiders1.7%
% institutions92.4%
Last declaration on 15 September 2026
Declarations94 total
160,944 shares@ US$13.610.27% mcap30.4% of flowCommon StockSEC:0001607969-26-000002:0
130,000 shares@ US$18.4620.30% mcap33.3% of flowCommon StockSEC:0001607969-26-000002:1
8,121 shares@ US$18.480.019% mcap32.5% of flowCommonSEC144:0001959173-26-006919
130,000 shares@ US$18.46210.30% mcap33.3% of flowCommonSEC144:0001959173-26-006899
3,974 sharesCommon StockSEC:0001681622-26-000071:0
1,145 shares@ US$18.490.0027% mcap35.6% of flowCommon StockSEC:0001681622-26-000071:1
4,510 shares@ US$11.1410.9% of flowCommon StockSEC:0001592005-26-000005:0
8,483 sharesCommon StockSEC:0001681622-26-000014:0
8,483 sharesCommon StockSEC:0001278861-26-000004:0
8,483 sharesCommon StockSEC:0001217440-26-000002:0
8,483 sharesCommon StockSEC:0001701927-26-000003:0
8,483 sharesCommon StockSEC:0001532367-26-000002:0
10,339 sharesCommon StockSEC:0001413087-26-000003:0
4,664 sharesCommon StockSEC:0001681622-25-000127:0
4,664 sharesCommon StockSEC:0001681622-25-000126:0
26,652 sharesCommon StockSEC:0001681622-25-000125:0
6,665 sharesCommon StockSEC:0001681622-25-000123:0
7,063 sharesCommon StockSEC:0001681622-25-000122:0
3,174 shares@ US$12.340.0050% mcap64.4% of flowCommon StockSEC:0001681622-25-000093:0
3,000 shares@ US$10.496.8% of flowCommon StockSEC:0001681622-25-000086:0
2,575 shares@ US$7.774.4% of flowCommon StockSEC:0001681622-25-000077:0
3,689 sharesCommon StockSEC:0001681622-25-000066:0
4,760 sharesCommon StockSEC:0001681622-25-000067:0
8,749 shares@ US$11.247.8% of flowCommon StockSEC:0001681622-25-000047:0
4,007 shares@ US$12.8111.1% of flowCommon StockSEC:0001681622-25-000045:0
25 of 94 declarations
About Varex Imaging Corp
Varex Imaging Corp. (Nasdaq: VREX) is a US-based specialized X-ray imaging technology company listed on the NASDAQ market in the United States. The company designs, manufactures, sells, and services critical components and subsystems used in medical imaging systems, as well as industrial and security inspection applications. Its core portfolio includes X-ray tubes, digital and photon-counting detectors, image-processing software, associated workstations, and other high-voltage and imaging-related components. In practical terms, Varex is a mission-critical supplier to OEMs that build imaging platforms for hospitals, security inspection, and industrial workflows. ([vareximaging.com](https://www.vareximaging.com/news/varex-announces-successful-completion-of-debt-refinancing/?utm_source=openai))
The company’s roots date back to the 1930s through Eimac Products and later the growth of Varian’s X-ray imaging franchise. Varex was then spun out as an independent company to house and expand the imaging components business. That heritage gives it a long operating track record and a deep technical base in imaging hardware and related software. Its global headquarters are in Salt Lake City, Utah, which places the company in a US innovation corridor with strong manufacturing and med-tech links. ([vareximaging.com](https://www.vareximaging.com/about-us/?utm_source=openai))
Read moreShow less
From a competitive standpoint, Varex occupies a strategically important niche. It is not primarily a systems vendor; instead, it supplies the core imaging building blocks that enable its customers to differentiate their own products. This makes Varex relevant across multiple end markets: medical imaging, non-intrusive cargo and vehicle screening, and selected industrial inspection uses. The model provides some diversification, but it also leaves the company exposed to customer capex cycles, technology adoption, and pricing pressure in component markets. ([vareximaging.com](https://www.vareximaging.com/news/varex-announces-successful-completion-of-debt-refinancing/?utm_source=openai))
Its product set spans CT tubes, flat-panel detectors, photon-counting detectors, image-processing software, 3D reconstruction tools, and cargo inspection systems. Recent company updates show a more active commercial and financial backdrop: Varex announced about $25 million of cargo inspection orders in May 2025, launched the XRD 3131N detector for high-throughput EV battery inspection, and completed a debt refinancing in March 2026 with total commitments of $490 million maturing in 2031. Management said the refinancing should improve financial flexibility and reduce annualized cash interest expense. These events highlight a business focused on both product execution and balance-sheet repair. ([vareximaging.com](https://www.vareximaging.com/news/varex-announces-non-intrusive-cargo-inspection-systems-orders-valued-at-25-million/?utm_source=openai))
For international investors, Varex is best viewed as a niche med-tech and industrial imaging infrastructure name rather than a broad healthcare company. Its exposure to CT replacement demand, security screening, and EV-related inspection trends can support long-term relevance, but the stock remains sensitive to OEM demand, macro cycles, and capital structure execution. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1681622/000168162225000106/exhibit991-q425earningsrel.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
